Russian Federation
Russian Federation
from 01.01.2021 until now
Russian Federation
Russian Federation
UDK 50 Общие вопросы математических и естественных наук
At the moment, according to ROSSTAT statistics, the incidence of chickenpox from 2007 to 2020 affects approximately 450-600 per 100 thousand people, and also ranks third among viral diseases, not including tuberculosis and HIV, after SARS and intestinal infections, causing visible damage to the economy. The significance of the incidence of chickenpox remains at the same level, rang-ing from 21.3 to 30.5% of the total number of infectious diseases. In addition, according to data for 2022, patients have become more difficult to tolerate illness. Accordingly, the inclusion of vaccination in the mandatory program of specific prevention of chickenpox is an urgent issue. The development of specific prevention against chickenpox began in the mid-90s of the last century. In countries where routine vaccination of children against chickenpox has been introduced, it has had a positive impact on disease prevention and control. However, in a number of European countries, except Germany and Greece, measures have been postponed to make a decision on the inclusion of chickenpox vaccination in the National Vaccination Calendar. Some countries offer routine im-munization programs for children, others offer targeted programs, and in many countries the vac-cine is only available privately. Therefore, an important point is the study of this issue by our do-mestic colleagues.
Varicella Zoster; Chickenpox; vaccination; countries; incidence; statistics.
1. Magamedeminova, M. M. Osobennosti techeniya vetryanoy ospy u vzroslyh / M. M. Magamedeminova, V. M. Korotkih, S. R. Polyakova. — Tekst : neposredstvennyy // Molodoy uchenyy. — 2020. — № 8 (298). — S. 75-76. — URL: https://moluch.ru/archive/298/67556/. EDN: https://elibrary.ru/EIFKGT
2. Kuz'mina T. Yu., Tihonova Yu. S., Tihonova E. P., Babushkin A. O., Andronova N. V. Osobennosti techeniya vetryanoy ospy u vzroslyh. Sibirskoe medicinskoe obozrenie, 2013, 2.
3. Ozaki, T., & Asano, Y. (2016). Development of varicella vaccine in Japan and future prospects. Vaccine, 34(29), 3427–3433. https://doi.org/10.1016/j.vaccine.2016.04.059.
4. Cvjetković D, Jovanović J, Hrnjaković-Cvjetković I. Primoinfekcija virusom varicele zoster--savremena saznanja i dijagnosticko-terapijski pristup [Primary varicella-zoster virus infection--current knowledge, diagnostic and therapeutic approaches]. Med Pregl. 2000;53(5-6):272-276.
5. Afonina Natal'ya, Miheeva Irina. Sovremennaya epidemiologicheskaya harakteristika vetryanoy ospy v rossii. One health & Risk management. vol. 1, issue 1 April 2020. DOI:https://doi.org/10.5281/zenodo.3700955.
6. Riccò, M., Ferraro, P., Zaffina, S., Camisa, V., Marchesi, F., Franzoso, F. F., Ligori, C., Fiacchini, D., Magnavita, N., & Tafuri, S. (2024). Immunity to Varicella Zoster Virus in Healthcare Workers: A Systematic Review and Meta-Analysis (2024). Vaccines, 12(9), 1021. https://doi.org/10.3390/vaccines12091021.
7. Rafferty, E. R. S., McDonald, W., Osgood, N. D., Doroshenko, A., & Farag, M. (2021). What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(1), 50–60. https://doi.org/10.1016/j.jval.2020.10.004.
8. Dhillon, S., Curran, M.P. Live Attenuated Measles, Mumps, Rubella, and Varicella Zoster Virus Vaccine (Priorix-Tetra™). Pediatr-Drugs 10, 337–347 (2008). https://doi.org/10.2165/00148581-200810050-00007. EDN: https://elibrary.ru/EJZMBQ
9. Fortunato, F., Musco, A., Iannelli, G., Meola, M., Luigi Lopalco, P., & Martinelli, D. (2024). Effectiveness of the combined MMRV Priorix-Tetra™ vaccine against varicella in a large Italian region: A case-control study. Vaccine, 42(7), 1608–1616. https://doi.org/10.1016/j.vaccine.2024.02.002.
10. Krow-Lucal E, Marin M, Shepersky L, Bahta L, Loehr J, Dooling K. Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1465–1470. DOI: http://dx.doi.org/10.15585/mmwr.mm7146a1. EDN: https://elibrary.ru/WMCSLF
11. Ahern, S., Walsh, K. A., Paone, S., Browne, J., Carrigan, M., Harrington, P., Murphy, A., Teljeur, C., & Ryan, M. (2023). Clinical efficacy and effectiveness of alternative varicella vaccination strategies: An overview of reviews. Reviews in medical virology, 33(1), e2407. https://doi.org/10.1002/rmv.2407.
12. Ahern, S., Walsh, K. A., Paone, S., Browne, J., Carrigan, M., Harrington, P., Murphy, A., Teljeur, C., & Ryan, M. (2023). Safety of varicella vaccination strategies: An overview of reviews. Reviews in medical virology, 33(2), e2416. https://doi.org/10.1002/rmv.2416.
13. Prymula, R., Bergsaker, M. R., Esposito, S., Gothefors, L., Man, S., Snegova, N., Štefkovičova, M., Usonis, V., Wysocki, J., Douha, M., Vassilev, V., Nicholson, O., Innis, B. L., & Willems, P. (2014). Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet (London, England), 383(9925), 1313–1324. https://doi.org/10.1016/S0140-6736(12)61461-5.
14. Evropeyskiy centr profilaktiki i kontrolya zabolevaniy (ECDC). Informacionnyy byulleten' o vetryanoy ospe. ECDC; 2021. Po sostoyaniyu na 12 aprelya 2022 goda. https://www.ecdc.europa.eu/en/varicella/facts.
15. Centry po kontrolyu i profilaktike zabolevaniy . Vetryanaya ospa (Varicella); 2021. Po sostoyaniyu na 16 maya 2022 goda. https://www.cdc.gov/chickenpox/hcp/index.html.
16. Kauffmann, F., Bechini, A., Bonanni, P., Casabona, G., & Wutzler, P. (2020). Varicella vaccination in Italy and Germany - different routes to success: a systematic review. Expert review of vaccines, 19(9), 843–869. https://doi.org/10.1080/14760584.2020.1825947.
17. Varela, F. H., Pinto, L. A., & Scotta, M. C. (2018). Global impact of varicella vaccination programs. Human Vaccines & Immunotherapeutics, 15(3), 645–657. https://doi.org/10.1080/21645515.2018.1546525.
18. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec. 2014;89(25):265–287. Available at: https://www.who.int/ wer/2014/wer8925.pdf?ua=1.
19. Denny J.T., Rocke Z.M., McRae V.A., Denny J.E., Fratzola C.H., Ibrar S. et al. Varicella Pneumonia: Case Report and Review of a Potentially Lethal Complication of a Common Disease. J Investig Med High Impact Case Rep. 2018;6. doi:https://doi.org/10.1177/2324709618770230.
20. . Bechini A., Boccalini S., Baldo V., Cocchio S., Castiglia P., Gallo T. et al. Impact of universal vaccination against varicella in Italy. Hum Vaccin Immunother. 2015;11(1):63–71. doi:https://doi.org/10.4161/hv.34311.
21. Heywood A.E., Wang H., Macartney K.K., McIntyre P. Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study. Bull World Health Organ. 2014;92(8):593–604. doi:https://doi.org/10.2471/BLT.13.132142 EDN: https://elibrary.ru/UQJBGH
22. Dulović O., Gvozdenović E., Nikolić J., Spurnić A. R., Katanić N., KovarevićPavićević D. Varicella complications: is it time to consider a routine varicella vaccination? Vojnosanit Pregl. 2010;67(7):523–529. doi:https://doi.org/10.2298/vsp1007523d.
23. Yilmaz C., Gaksen H. Severe neurological complications of chickenpox. Eur J Gen Med. 2005;2(4):177–179. Available at: http://www.bioline.org.br/ pdf?gm05040.
24. Popova A.Yu., Ezhlova E.B., Mel'nikova A.A., Miheeva I.V. Realizaciya programmy immunizacii v Rossiyskoy Federacii na sovremennom etape: vyzovy, vozmozhnosti, perspektivy. Zhurnal mikrobiologii, epidemiologii i immunobiologii. 2018;(6):3–10. doi:https://doi.org/10.36233/0372-9311-2018-6-3-10. EDN: https://elibrary.ru/ZDNSLB
25. Ilunina L.M., Agisheva L.A., Berezhnaya Yu.A., Radchenko O.M. Vetryanaya ospa u detey. Zhurnal infektologii. 2015;7(4s):75–76. doi:https://doi.org/10.22625/2072- 6732-2015-7
26. Civen R., Marin M., Zhang J., Abraham A., Harpaz R., Mascola L., Bialek S.R. Update on incidence of herpes zoster among children and adolescents following implementation of varicella vaccination, Antelope Valley, CA, 2000–2010. Pediatr Infect Dis J. 2016;35(10):1132–1136. doi: 10.1097/ INF.0000000000001249.
27. Leung J., Marin M. Update on trends in varicella mortality during the varicella vaccine era-United States, 1990–2016. Hum Vaccin Immunother. 2018;14(10):2460–2463. doi:https://doi.org/10.1080/21645515.2018.1480283.
